Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...